Six healthy young male volunteers at a contract research organization were enrolled in the first phase 1 clinical trial of TGN1412, a novel superagonist anti-CD28 monoclonal antibody that directly ...

In physiological activation of naïve T cells, CD28 recruitment by B7 engagement sustains formation of the immunological synapse, thereby lowering the antigen threshold and increasing T-cell ...

Rondo Therapeutics’ proprietary platform features CD28-targeting binders with a wide range of co-stimulatory potencies designed to boost T cell-mediated tumor killing and overcome T cell ...

Rondo Therapeutics Publishes Preclinical Data on RNDO-564, a Novel CD28 x Nectin-4 Co-Stimulatory Bispecific Antibody for the Treatment of Bladder Cancer -RNDO-564 is designed to deliver safe and ...

“ Xencor has rapidly generated multiple CD28 co-stimulatory bispecific antibodies with potential broad applicability across a range of solid tumors, and each of these programs has demonstrated ...

Regeneron is rethinking development of its prostate cancer bispecific after two patients died in a clinical trial. The deaths prompted the Big Biotech to stop enrolling patients to receive ...

With analysts looking for an increase in responses for Regeneron's phase 1/2 solid tumor trial, a fresh data slice shows just one complete response.

Adding CD28 costimulation to cord blood-derived chimeric antigen receptor (CAR) natural killer (NK) cells targeting CD70+ cancers significantly enhanced antitumor efficacy and long-term ...

Their studies in mice showed that blocking superantigen-CD28 binding by administering peptides that compete for the binding site on CD28 prevents induction of the cytokine storm. Led by Raymond ...

CD28 is considered to be the main co-stimulatory molecule, and the second signal has the ability to activate T cells, secrete cytokines, and express cytokine receptors.